$393.84-22.47 (-5.40%)
Synopsys, Inc.
Synopsys, Inc. in the Technology sector is trading at $393.84. Wall Street consensus targets $544.97 (26 analysts), implying a +38.4% move over the next 12 months. The stock is currently near its 52-week low of $366.00, remaining 11.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.28B↓ | $2.41B↑ | $2.25B↑ | $1.74B↑ | $1.60B |
| Gross Profit | $1.65B↓ | $1.77B↑ | $1.60B↑ | $1.36B↑ | $1.29B |
| Operating Income | $236.32M↓ | $321.33M↑ | $121.39M↓ | $165.27M↓ | $376.43M |
| Net Income | $17.11M↓ | $64.96M↓ | $448.70M↑ | $242.51M↓ | $345.33M |
Synopsys, Inc. provides design IP solutions in the semiconductor and electronics industries. It operates in two segments, Design Automation and Design IP. The company offers Digital and Custom IC Design solution that provides digital design implement...

Synopsys is facing restructuring pressure, but resilient results and AI-driven demand could keep its investment prospects solid.

Both software players are riding the AI wave, but PTC offers a clearer forward path with stronger growth and profitability, while Oracle asks investors to fund a massive, costly buildout.

The design software giant is betting on a new strategy, and its stock history offers a strong blueprint for buying on weakness.

Synopsys powers nearly every advanced chip on the planet, yet its stock has cratered while the broader market surged, and Wall Street analysts are betting that gap closes in a hurry.

Synopsys (SNPS) booked revenue of $2.477 billion in fiscal Q3 2026, up about 42% year over year, and the shares have still lost about 30% over the past twelve months. Look past that headline at the line underneath it: EDA grew 8.5%. That single-digit number is the pace of the design tools business Synopsys had before the Ansys deal.
Academic risk and quality models computed from SNPS's own filings and price history, not from analyst opinion.
Weak: only 3 of 9 fundamental-health tests pass, which is the range associated with deteriorating fundamentals.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M above -1.78, the threshold where the model flags an elevated likelihood of earnings manipulation.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.